Attention Turns to Merck and AstraZeneca After Courts’ 340B Contract Pharmacy Rulings

The timing of the government’s forthcoming decision on the legality of Merck’s 340B contract pharmacy policy, and the grounds for its decision, are two big questions hovering over the 340B program.

The smoke is still clearing from three federal district judges’ recent decisions in drug manufacturers Lilly, Sanofi, Novo Nordisk, Novartis, and United Therapeutics’ 340B contract pharmacy lawsuits. In the rulings’ wake, we are keeping close tabs on what happens next

Read More »

Hospitals, Drug Manufacturers, and Lawyers Give their Takes on 340B Contract Pharmacy Rulings

A hospital group, drug manufacturers, and health care lawyers gave 340B Report their views on recent court rulings in five 340B contract pharmacy lawsuits.

A hospital group says two federal district judges got it right, but one got it wrong, on whether drug manufacturers are legally bound to provide 340B drug discounts for drugs dispensed at contract pharmacies.

In a Nov. 6 statement, 340B

Read More »

Two New Studies on Hospital and Health Center Participation in 340B

Rush University Medical Center was included in a JAMA Internal Medicine study of what top hospitals charge commercial insurers for clinician-administered drugs.

A new research letter published in JAMA Internal Medicine found substantial variation among 17 “top-performing” hospitals—14 of them enrolled in 340B—in what they charge commercial insurers for clinician-administered drugs.

Meanwhile, new research published in Journal of Healthcare Quality found that

Read More »

Breaking News

Breaking: Another Federal Judge Issues a Mixed Opinion in 340B Contract Pharmacy Litigation, this Time in Novartis and United Therapeutics’ Cases

U.S. District Judge Dabney Friedrich last night issued the second court ruling of the day involving drug manufacturers’ denials of and limitations on 340B pricing when covered entities use contract pharmacies.

A federal district judge last night issued the second court ruling of the day involving drug manufacturers’ denials of and limitations on 340B pricing when covered entities use contract pharmacies. Like the day’s earlier ruling, this one too was mixed,

Read More »

Breaking News

Breaking: Federal Judge Hands Down Mixed Opinion in Sanofi and Novo Nordisk’s 340B Contract Pharmacy Lawsuits

U.S. Chief District Judge Freda Wolfson ruled today that Sanofi and Novo Nordisk's 340B contract pharmacy policies violate the 340B statute. But she declined to decide whether the 340B statute permits covered entities to use multiple or unlimited contract pharmacies.

A federal district judge this afternoon upheld the federal government’s finding that drug manufacturers Sanofi and Novo Nordisk cannot unilaterally impose restrictions on offers of 340B pricing to covered entities and that their policies must cease.

U.S. Chief District Judge

Read More »

Feds Ask Judges to Follow Judge in Lilly Case and Validate HRSA’s Take on 340B Contract Pharmacy

DOJ has asked judges in five manufacturers' 340B contract pharmacy cases to follow to follow the lead of the judge in Lilly’s case and hold that these five companies’ contract pharmacy policies are illegal.

The federal government on Tuesday urged the judges in AstraZeneca, Novartis, Novo Nordisk, Sanofi, and United Therapeutics’ separate 340B contract pharmacy lawsuits to follow the lead of the judge in Lilly’s case and hold that these five companies’ contract pharmacy

Read More »

Biden Taps Judge in AstraZeneca’s 340B Lawsuit for Appeals Court Seat

Leonard Stark, the federal district judge assigned to AstraZeneca’s 340B contract pharmacy lawsuit, was nominated yesterday to fill a vacancy on a federal appeals court in Washington, D.C.

President Biden yesterday nominated the federal district judge assigned to AstraZeneca’s 340B contract pharmacy lawsuit to fill a vacancy on a federal appeals court in Washington, D.C.

The White House announced U.S. District Judge Leonard Stark’s nomination to be a

Read More »

Kalderos Tells Hospitals its Service to Turn 340B Discounts into Rebates is Operational

A screenshot of drug industry vendor Kalderos' email announcement this week that 340B Pay, its service to let drug companies pay 340B ceiling prices as rebates instead of as discounts, is operational.

Drug discount management company Kalderos sent email messages to 340B hospitals this week once again announcing the launch of its 340B Pay service to let drug companies pay 340B ceiling prices as back-end rebates instead of as front-end discounts on

Read More »

Limited Medicare Drug Price Negotiation Placed into Reconciliation Bill; 340B Impact Unclear

U.S. Senate Majority Leader Chuck Schumer (D-N.Y.) announced on Tuesday that congressional Democrats and the White House reached agreement on federal drug pricing legislation. | C-SPAN

Democratic lawmakers have come to an agreement for placing a limited drug price negotiation plan for the Medicare program into the Build Back Better bill, but how it will impact the 340B program remains to be seen.

“By empowering Medicare

Read More »

3 Requirements for Exceptional Specialty Pharmacy Patient Satisfaction

SPONSORED CONTENT

The Net Promoter Score® (NPS) offers an objective measurement of what is arguably one of healthcare’s most critical—but subjective—areas of focus: patient satisfaction. It is a cross-industry standardized index designed to measure people’s willingness to recommend a company’s products or services to others. While traditional customer satisfaction surveys usually measure a customer’s perception of a specific interaction, NPS measures a customer’s overall attitude toward your brand over time.

Within healthcare, NPS is a strong gauge of how satisfied patients feel with the care they receive. Therefore, it’s noteworthy when organizations receive a significantly higher NPS than the average NPS for other companies offering similar products or services.

Zitter Insights, a division of Managed Markets Insight & Technology (MMIT), conducts a quarterly NPS survey to assess patient satisfaction with specialty pharmacies. In the Q2 2021 fielding, the results revealed that Trellis Rx received an average NPS of 90. By comparison, the overall average NPS across health system, independent, payer, retail, and pharmacy

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report